Haifa, Israel May 29, 2007 New early data showed that an investigational device that specifically targets rapidly growing cancer cells with intermediate frequency electrical fields -- called Tumor-Treating Fields (TTFields) -- more than doubled the median overall survival rates in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of malignant brain tumor. These survival rates observed in the data were compared to historical data. This research, which includes the results of cell culture, animal and early phase human trials, appears in the current issue of the Proceedings of the National Academy of Sciences (PNAS).
The device, called the Novo-TTF, uses electrical fields to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off instead of dividing and growing. Healthy brain cells rarely divide and have different electrical properties than cancerous brain cells. This allows the device to target cancer cells without affecting the healthy cells.
At the time of publication, researchers found that among the 10 patients with recurring GBM treated with the Novo-TTF, the median length of time to disease progression was 26.1 weeks; progression free survival at six months was 50 percent; and median overall survival was 62.2 weeks. This is more than double the rates reported in historical data approximately 9.5 weeks, 15.3%, and 29.3 weeks, respectively.
"The novel mechanism of action of the Novo-TTF relies on the physical properties of the cancer cells, their shape and size, rather than the chemical make-up. We believe that this distinction enables the device to stop local proliferation and metastasis of cancer, which would explain the efficacy observed in these early findings," said Dr. Elion Kirson lead author and Vice President of Research and Development, NovoCure. "Based on our preliminary research, we believe that there is a
'"/>
Contact: Marissa Green
marissa.green@edelman.com
212-704-8250
Edelman Public Relations
29-May-2007